TrialJournal of neurology2025

Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.

Carolina Barnett-Tapia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.